Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL4816262 | 0.88 | P2RX7 (0.41) | P2RX7LMNAALDH1A1KDM4ENAPRT | |
| Fumaric Acid SCHEMBL4976045 | 0.83 | KDM4E (0.45) | P2RX7LMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL244917 | 0.83 | — | — | |
| SCHEMBL17275087 | 0.80 | LMNA (0.43) | P2RX7LMNAHTTALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL4489525 | 0.80 | — | — | |
| Acetic Acid SCHEMBL31083905 | 0.75 | ALDH1A1 (0.53) | LMNAALDH1A1KDM4ESMN1; SMN2CYP1A2 | |
| Acetic Acid SCHEMBL3859492 | 0.75 | ALDH1A1 (0.53) | LMNAALDH1A1KDM4ESMN1; SMN2CYP1A2 | |
| Acetic Acid SCHEMBL1062315 | 0.75 | ALDH1A1 (0.53) | LMNAALDH1A1KDM4ESMN1; SMN2CYP1A2 | |
| Acetic Acid SCHEMBL7837904 | 0.73 | HSP90AA1 (0.63) | P2RX7LMNAHTTALDH1A1KDM4E | |
| Acetic Acid SCHEMBL15174453 | 0.72 | NOS3 (0.42) | P2RX7HTTALDH1A1NAPRTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666814-A | Atorvastatin non-preparation method | 济南鸿湾生物技术有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2014174529-A2 | POLYMORPHS OF AVANAFIL | HETERO RESEARCH FOUNDATION (IN) | 2014-10-30 | — | — | WO | disclosed |
| US-8399663-B2 | Salt of 1,3,5-triazine-2,4,6-triamine derivative | ASTELLAS PHARMA INC. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120088772-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | ASTELLAS PHARMA INC. (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2413940-A1 | COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100256151-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| WO-2010114163-A1 | COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256152-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256152-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA | KCNAB1, KCNN1, SCN1A | ADRB2 904/4885P2RX7 2145/4885LMNA 4682/4885 |
| US-20120088772-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | SLC6A3, ATP1A2, SLC6A1 | ADRB2 587/4885P2RX7 1198/4885LMNA 4763/4885 |
| US-20100256151-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | FH, FAH, GOT1 | ADRB2 3616/4885P2RX7 2881/4885LMNA 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.